What led you to concentrate there?

This goes back to the lessons of what we were naive about and what we weren't, right? We had started with this idea in dirty drugs in, uh, a class of receptors called GPCRs, where there's a lot of polypharmacology where a small molecule can hit many things, and that's essential for their function, and bias, which is multiple pathways off the same target.

We switched largely because we began to realize that if we wanted to build scale and our own commercial drugs, it's really hard to do that in a large, complex disease area.

Your only option really is to transact the asset where value and flex.

And we are trying to build a company that can build scale over time.

What we saw was small molecule correctors that we landed on are more protectable in the sense that they're really hard to build.

No one else has really good ways to build them.

What actually is happening inside the platform when you run one of these experiments, and why is it so unique?

Well, so for those who aren't familiar with this, can you just tell the story in short? Sure.

Yeah, you know, around Thanksgiving in 2024, my daughter started developing a swelling above her eye, her left eye.

And, you know, we went to the pediatrician.

They thought it was a stye.

We iced it and it just kept on getting worse.

My brother got married in mid-December.

We went there and it was just getting worse and worse.

What was in those models that simulated this to a high degree of accuracy?